Twist Bioscience (NASDAQ:TWST) Insider Sells $124,768.44 in Stock

Key Points

• Dennis Cho, an insider at Twist Bioscience, sold 3,876 shares of stock on October 6 for a total of $124,768.44, reducing his ownership position by 3.78% to 98,710 shares.
• Twist Bioscience reported a quarterly earnings loss of ($0.47) per share, which beat analysts' expectations, and had a revenue of $96.06 million, exceeding estimates of $95.52 million.
• Equities analysts maintain a "Moderate Buy" consensus rating for Twist Bioscience with a target price of $48.50, despite recent downward adjustments in price objectives by institutions.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) insider Dennis Cho sold 3,876 shares of the business's stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $32.19, for a total value of $124,768.44. Following the sale, the insider directly owned 98,710 shares of the company's stock, valued at approximately $3,177,474.90. This trade represents a 3.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Dennis Cho also recently made the following trade(s):

• On Monday, September 22nd, Dennis Cho sold 233 shares of Twist Bioscience stock. The shares were sold at an average price of $27.56, for a total value of $6,421.48.
• On Monday, September 15th, Dennis Cho sold 94 shares of Twist Bioscience stock. The shares were sold at an average price of $25.33, for a total value of $2,381.02.
• On Monday, September 8th, Dennis Cho sold 269 shares of Twist Bioscience stock. The stock was sold at an average price of $25.76, for a total value of $6,929.44.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock traded up $1.67 on Wednesday, reaching $32.79. 2,438,969 shares of the company were exchanged, compared to its average volume of 1,273,207. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. The company's 50-day moving average is $27.76 and its two-hundred day moving average is $32.84. The firm has a market cap of $1.98 billion, a price-to-earnings ratio of -22.61 and a beta of 2.38. Twist Bioscience Corporation has a 1-year low of $24.07 and a 1-year high of $55.33.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. The business had revenue of $96.06 million for the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on TWST shares. Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th. Evercore ISI reduced their price objective on Twist Bioscience from $46.00 to $42.00 and set an "outperform" rating for the company in a research note on Tuesday. Barclays reduced their price objective on Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating for the company in a research note on Thursday, October 2nd. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Twist Bioscience in a research note on Wednesday. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Twist Bioscience presently has a consensus rating of "Moderate Buy" and a consensus target price of $48.50.

Institutional Trading of Twist Bioscience

Several hedge funds and other institutional investors have recently modified their holdings of TWST. GAMMA Investing LLC increased its position in Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after buying an additional 303 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock worth $85,000 after purchasing an additional 302 shares during the period. Geneos Wealth Management Inc. bought a new position in shares of Twist Bioscience in the second quarter worth about $97,000. Bayforest Capital Ltd lifted its position in shares of Twist Bioscience by 49.3% in the 1st quarter. Bayforest Capital Ltd now owns 4,860 shares of the company's stock worth $191,000 after acquiring an additional 1,604 shares during the period. Finally, Pallas Capital Advisors LLC bought a new position in Twist Bioscience in the first quarter worth $201,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.